Yaohai Bio-Pharma and Topgene Bio Establish Strategic Partnership

March 19, 2025 – Yaohai Biopharmaceutical Co., Ltd. (Yaohai Bio-Pharma) and Hubei Topgene Biotechnology Group Co., Ltd. (Topgene Bio) have officially entered a strategic partnership, marking a significant step toward advancing biopharmaceutical research and development. The agreement was formally signed by Wang Manchao, Director and General Manager of Yaohai Bio-Pharma, and Ren Xidong, Chairman of Topgene Bio, symbolizing the beginning of a strong collaboration in innovative drug development.

Unlocking Synergies for Comprehensive R&D Solutions

This partnership is built upon a shared vision to enhance the biopharmaceutical innovation ecosystem by leveraging the complementary strengths of both companies. By integrating their expertise, Yaohai Bio-Pharma and Topgene Bio will provide one-stop solutions for the entire R&D cycle, offering services in nonclinical evaluation, biological analysis, strain engineering, and regulatory support. Through this collaboration, both parties will work to optimize resource utilization, improve service efficiency, and build a more robust and globally competitive R&D service platform.

With an emphasis on compliance and innovation, the two companies will streamline drug development workflows, helping biopharmaceutical enterprises shorten R&D timelines and reduce costs while maintaining the highest regulatory and quality standards. This partnership will establish a long-term, mutually beneficial cooperation model, ensuring sustained innovation in the industry.

Expanding Market Reach Through Innovation

As the global biopharmaceutical industry continues to evolve, Yaohai Bio-Pharma and Topgene Bio will deepen their collaboration to explore new opportunities and extend their reach. By embracing a dynamic, market-driven approach, the partnership will foster breakthroughs in key areas of drug research and development, while enhancing China’s influence in the global life sciences sector.

About Topgene Bio

Founded in 2009 and headquartered in Optics Valley BioCity, Wuhan, Topgene Bio is a high-tech Contract Research Organization (CRO) specializing in large-animal studies and new drug evaluation. The company is dedicated to advancing pharmaceutical innovation and serving human health, with a comprehensive service platform that integrates industry, academia, and research.

About Yaohai Bio-Pharma

Established in 2010, Yaohai Bio-Pharma is an industry-leading CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in microbial expression systems. As a national high-tech enterprise, the company is focused on developing recombinant proteins and peptides, nucleic acid-based therapies, nanobody drugs, recombinant plasmids, and next-generation recombinant vaccines.

With an integrated CRO/CDMO/MAH platform, Yaohai Bio-Pharma provides end-to-end services, supporting clients from early-stage research and IND submission to clinical sample production and commercial-scale manufacturing. To date, the company has successfully delivered over 200 projects, offering regulatory-compliant, high-efficiency solutions to biopharmaceutical enterprises worldwide.

Guided by its mission of “Driving Global Standards, Accelerating Drug Development, and Advancing Human Health,” Yaohai Bio-Pharma continues to expand its R&D capabilities, enhance its production and quality management systems, and support global pharmaceutical innovation.

We are also actively seeking institutional or individual global partners. We offer the most competitive compensation in the industry. If you have any questions, please feel free to contact us at [email protected]